Oncology Central

Genetic test may lead to more effective chemotherapy for triple-negative breast cancer

A major clinical trial has reported that women with advanced triple-negative breast cancer who have faults in their BRCA genes do much better on the chemotherapy drug carboplatin than standard treatment.

In this study, the researchers discovered that advanced ‘triple-negative’ breast cancer patients who have inherited a BRCA mutation are twice as likely to benefit from carboplatin as docetaxel.

Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.




News Headlines

Leave A Comment

Please wait...

Would you like access to more immuno-oncology content?

Register with Oncology Central to find out the latest news, opinions and journal articles published in the oncology field by leading experts.